The briefing yesterday was PACKED - full of suits, stockbrokers,...

The briefing yesterday was PACKED - full of suits, stockbrokers, investors, pharma types, standing room only. GK ran through the slide presentation that was released in the morning, but took time to expand on key aspects.

The TROG prostate trial at 5 sites is steaming ahead, with patients identified and getting ready to start. Treatment will be quick at just two weeks, responses should be evident after six weeks. Must expect dramatic results. Proof-of-concept in humans should be evident by end of 2017, Phase III registration trial planned to start in about 12 months.

Team of scientists in Melbourne attempting to identify mechanism by which an abscopal effect is achieved, implying that they have been able to induce this effect in animals using NOX66. GK expects non-irradiated tumours as well as irradiated tumours in humans to respond to treatment.

Commercial potential obvious. Immunotherapy treatment costs $100K to $500K but negligible response, NOX will make sure treatment does not require house to be sold. Governments/patients would also save cost of treatment of side effects.

Brachytherapy trial at St Vincent's also steaming ahead, with patients undergoing pre-treatment preparation.

Results from Georgia chemo trials will be updated at an ESMO conference later this year. GK expects 800 mg to be the best NOX66 dose for clinical trials (makes sense - one 400 mg suppository every 12 hours for two weeks means that a therapeutic level of Idronoxil will be present in the body at all times).

GK presentation on NYRADA potential was eye-opening. Noxopharm has its hands full with its oncology program, developing NYRADA assets in-house would dilute funds and distract management, intention is for GK to be Chairman but for a separate group to develop science to the point that an IPO in the US can take place. No dilution for shareholders if funds raised separately. The alternative is to let the opportunity whither in the bottom drawer. Seems like a no-brainer to me.

Presentation well received, lots of notes taken, no cynicism evident in questions from sophisticated audience.